| scholarly article | Q13442814 |
| P2093 | author name string | Richard Graves | |
| Tarun K Mandal | |||
| Sarala Pamujula | |||
| Valencia Walker | |||
| Grace Ledet | |||
| Shana Simon | |||
| P2860 | cites work | Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 |
| Mass vaccination: solutions in the skin. | Q30356970 | ||
| Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. | Q30398841 | ||
| Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. | Q30412748 | ||
| Nanostructured novel carrier for topical application | Q33359009 | ||
| Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial | Q34359432 | ||
| Formation and stability of nano-emulsions | Q35741588 | ||
| DNA delivery for vaccination and therapeutics through the skin | Q36393430 | ||
| Microemulsions as transdermal drug delivery vehicles | Q36537189 | ||
| Particle-based vaccines for transcutaneous vaccination | Q36960310 | ||
| Vaccine adjuvants: the dream becomes real | Q37235920 | ||
| Intradermal immunization improves protective efficacy of a novel TB vaccine candidate | Q37344775 | ||
| Formulation effects of topical emulsions on transdermal and dermal delivery | Q37365704 | ||
| Optimized subunit vaccine protects against experimental leishmaniasis | Q37439440 | ||
| Squalene emulsions for parenteral vaccine and drug delivery | Q37604157 | ||
| Nano-emulsions and Micro-emulsions: Clarifications of the Critical Differences | Q37807894 | ||
| Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion | Q39812986 | ||
| Nanoemulsion components screening and selection: a technical note. | Q41989363 | ||
| Formulation development and optimization using nanoemulsion technique: a technical note | Q41989945 | ||
| Nanoemulsions as vehicles for transdermal delivery of aceclofenac | Q42563739 | ||
| Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe | Q43204702 | ||
| Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies | Q43288357 | ||
| The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine | Q43546829 | ||
| Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation | Q46203048 | ||
| Multi-species assessment of electrical resistance as a skin integrity marker for in vitro percutaneous absorption studies | Q46232354 | ||
| Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. | Q46256790 | ||
| Impact of oil type on nanoemulsion formation and Ostwald ripening stability. | Q46319389 | ||
| Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions | Q46624026 | ||
| Increased bioavailability of a transdermal application of a nano-sized emulsion preparation. | Q51795279 | ||
| Guidelines for maintaining and managing the vaccine cold chain | Q79198688 | ||
| Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib | Q81316518 | ||
| Factors affecting the stability of O/W emulsion in BSA solution: stabilization by electrically neutral protein at high ionic strength | Q81356916 | ||
| Formulation and characterization of nanoemulsion-based drug delivery system of risperidone | Q82639969 | ||
| Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions | Q82754347 | ||
| Liposome surface charge influence on skin penetration behaviour | Q83767182 | ||
| Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid | Q83860035 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 370-379 | |
| P577 | publication date | 2013-04-19 | |
| P1433 | published in | Drug Development and Industrial Pharmacy | Q5308840 |
| P1476 | title | Development and in vitro evaluation of a nanoemulsion for transcutaneous delivery | |
| P478 | volume | 40 |
| Q38740621 | Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors |
| Q35087322 | Curcumin nanoemulsion for transdermal application: formulation and evaluation |
| Q27692376 | Effect of vaccine administration modality on immunogenicity and efficacy |
| Q36042944 | Monocyclic monoterpenes as penetration enhancers of ligustrazine hydrochloride for dermal delivery |
| Q64969549 | Nano-particle engineered atorvastatin delivery to support mesenchymal stem cell survival in infarcted myocardium. |
| Q40688909 | RGD peptide targeted lipid coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma |
| Q92540208 | Recent Advancements in Non-Invasive Formulations for Protein Drug Delivery |
| Q39014253 | Recent Advances in Lipid-Based Vesicles and Particulate Carriers for Topical and Transdermal Application. |
| Q47350239 | Topical Nano and Microemulsions for Skin Delivery. |
Search more.